Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus SUPRAX.
CEFOBID vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic